Cargando…
Molecular prevalence of parvovirus B19 among HIV1-infected patients in Iran
Background: Different outcomes of parvovirus B19 (B19V) infection in immunocompromised patients, including HIV1-infected persons, may be life-threatening. Considering the hematologic disorders associated with B19V infection, this study aimed to investigate the prevalence of B19V infection among HIV1...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Iran University of Medical Sciences
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6387811/ https://www.ncbi.nlm.nih.gov/pubmed/30815408 http://dx.doi.org/10.14196/mjiri.32.113 |
_version_ | 1783397646389477376 |
---|---|
author | Kiani, Seyed Jalal Javanmard, Davod Ghaffari, Hadi Tavakoli, Ahmad Mortazavi, Helya Sadat Bokharaei-Salim, Farah Bangaleh, Zahra Monavari, Seyed Hamidreza |
author_facet | Kiani, Seyed Jalal Javanmard, Davod Ghaffari, Hadi Tavakoli, Ahmad Mortazavi, Helya Sadat Bokharaei-Salim, Farah Bangaleh, Zahra Monavari, Seyed Hamidreza |
author_sort | Kiani, Seyed Jalal |
collection | PubMed |
description | Background: Different outcomes of parvovirus B19 (B19V) infection in immunocompromised patients, including HIV1-infected persons, may be life-threatening. Considering the hematologic disorders associated with B19V infection, this study aimed to investigate the prevalence of B19V infection among HIV1-infected individuals in Iran. Methods: Serum samples from 100 HIV1-infected patients were analyzed for B19 viral DNA using real-time PCR assay. COBAS TaqMan HIV-1 test was performed for quantitative measurements of HIV-1 RNA in the patients’ sera. Results: Real-time PCR analysis revealed that 10 out of 100 cases (10%) were positive for B19V infection. Across various age groups, the B19V infection was more prevalent among patients within the age range of 21-40 years. Higher prevalence of B19V infection was observed among HIV1-infected patients with a viral load of higher than 400 copies/mL. Conclusion: Despite limitations, this study may set the stage for further evaluations with larger sample sizes to elucidate the potential role of B19V in hematologic disorders, which may result in exacerbation of the disease in HIV1-infected patients. Moreover, as it has been shown that B19V infection can be treated using intravenous immunoglobulin (IVIG) therapy, available treatments may help improve the quality of life in HIV-infected persons. |
format | Online Article Text |
id | pubmed-6387811 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Iran University of Medical Sciences |
record_format | MEDLINE/PubMed |
spelling | pubmed-63878112019-02-27 Molecular prevalence of parvovirus B19 among HIV1-infected patients in Iran Kiani, Seyed Jalal Javanmard, Davod Ghaffari, Hadi Tavakoli, Ahmad Mortazavi, Helya Sadat Bokharaei-Salim, Farah Bangaleh, Zahra Monavari, Seyed Hamidreza Med J Islam Repub Iran Original Article Background: Different outcomes of parvovirus B19 (B19V) infection in immunocompromised patients, including HIV1-infected persons, may be life-threatening. Considering the hematologic disorders associated with B19V infection, this study aimed to investigate the prevalence of B19V infection among HIV1-infected individuals in Iran. Methods: Serum samples from 100 HIV1-infected patients were analyzed for B19 viral DNA using real-time PCR assay. COBAS TaqMan HIV-1 test was performed for quantitative measurements of HIV-1 RNA in the patients’ sera. Results: Real-time PCR analysis revealed that 10 out of 100 cases (10%) were positive for B19V infection. Across various age groups, the B19V infection was more prevalent among patients within the age range of 21-40 years. Higher prevalence of B19V infection was observed among HIV1-infected patients with a viral load of higher than 400 copies/mL. Conclusion: Despite limitations, this study may set the stage for further evaluations with larger sample sizes to elucidate the potential role of B19V in hematologic disorders, which may result in exacerbation of the disease in HIV1-infected patients. Moreover, as it has been shown that B19V infection can be treated using intravenous immunoglobulin (IVIG) therapy, available treatments may help improve the quality of life in HIV-infected persons. Iran University of Medical Sciences 2018-11-15 /pmc/articles/PMC6387811/ /pubmed/30815408 http://dx.doi.org/10.14196/mjiri.32.113 Text en © 2018 Iran University of Medical Sciences http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution NonCommercial 3.0 License (CC BY-NC 3.0), which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly. |
spellingShingle | Original Article Kiani, Seyed Jalal Javanmard, Davod Ghaffari, Hadi Tavakoli, Ahmad Mortazavi, Helya Sadat Bokharaei-Salim, Farah Bangaleh, Zahra Monavari, Seyed Hamidreza Molecular prevalence of parvovirus B19 among HIV1-infected patients in Iran |
title | Molecular prevalence of parvovirus B19 among HIV1-infected patients in Iran |
title_full | Molecular prevalence of parvovirus B19 among HIV1-infected patients in Iran |
title_fullStr | Molecular prevalence of parvovirus B19 among HIV1-infected patients in Iran |
title_full_unstemmed | Molecular prevalence of parvovirus B19 among HIV1-infected patients in Iran |
title_short | Molecular prevalence of parvovirus B19 among HIV1-infected patients in Iran |
title_sort | molecular prevalence of parvovirus b19 among hiv1-infected patients in iran |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6387811/ https://www.ncbi.nlm.nih.gov/pubmed/30815408 http://dx.doi.org/10.14196/mjiri.32.113 |
work_keys_str_mv | AT kianiseyedjalal molecularprevalenceofparvovirusb19amonghiv1infectedpatientsiniran AT javanmarddavod molecularprevalenceofparvovirusb19amonghiv1infectedpatientsiniran AT ghaffarihadi molecularprevalenceofparvovirusb19amonghiv1infectedpatientsiniran AT tavakoliahmad molecularprevalenceofparvovirusb19amonghiv1infectedpatientsiniran AT mortazavihelyasadat molecularprevalenceofparvovirusb19amonghiv1infectedpatientsiniran AT bokharaeisalimfarah molecularprevalenceofparvovirusb19amonghiv1infectedpatientsiniran AT bangalehzahra molecularprevalenceofparvovirusb19amonghiv1infectedpatientsiniran AT monavariseyedhamidreza molecularprevalenceofparvovirusb19amonghiv1infectedpatientsiniran |